Sugars And Splice: Glycobiology: The Next Frontier

Table of Carbohydrate Products Model of glycoprotein supplied by Seikagaku America Glycobiology. It has been called the "last frontier of pharmaceutical discovery." Hampered by a lack of economical and convenient tools, however, advances in glycobiology have been largely overshadowed by the rush to exploit PCR and the ready availability and comparative simplicity of the tools and enzymes for molecular biology. But that is changing. By all reports, the field of glycoprotein and carbo

Written byMichael Brush
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share


Glycobiology. It has been called the "last frontier of pharmaceutical discovery." Hampered by a lack of economical and convenient tools, however, advances in glycobiology have been largely overshadowed by the rush to exploit PCR and the ready availability and comparative simplicity of the tools and enzymes for molecular biology. But that is changing.


Model of glycoprotein supplied by Seikagaku America

By all reports, the field of glycoprotein and carbohydrate analysis and synthesis is making a comeback and has a bright future. Fueled by recent Food and Drug Administration requirements for the characterization of the oligosaccharide portions of recombinant proteins with pharmaceutical applications, new findings concerning the roles carbohydrates play in biological systems, and the rise of proteomics, industry insiders report much optimism about the growth of the carbohydrate analysis market.

The field of glycobiology has recently seen plenty of shuffling among the companies ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies